The aforementioned 5 genes (AXL, GAB1, ERBB2, NRP2, and ESR1) along with 13 pharmacological agents represent promising candidates for enhancing the treatment of osteoporosis and sarcopenia. The gene discussed is ERBB2; the disease is sarcopenia.